公开(公告)号：US20200009129A1

公开(公告)日：2020-01-09

申请号：US16510816

申请日：2019-07-12

Applicant: AMGEN INC.

Inventor： Matthew WEISS ,  Thomas DINEEN ,  Benjamin C. MILGRAM ,  Isaac E. MARX

IPC: A61K31/4704 ,  A61P29/02 ,  A61P11/14 ,  A61K31/501 ,  C07D403/12 ,  C07D413/12

Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

公开(公告)号：US20180369227A1

公开(公告)日：2018-12-27

申请号：US16062606

申请日：2016-12-19

Applicant: AMGEN INC.

Inventor： Matthew WEISS ,  Thomas DINEEN ,  Benjamin C. MILGRAM

IPC: A61K31/4704 ,  A61K31/501 ,  A61P11/14 ,  A61P29/02

CPC classification number: A61K31/4704 ,  A61K31/501 ,  A61P11/14 ,  A61P29/02 ,  C07D403/12 ,  C07D413/12

Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.